Immune protection of Hepatitis B vaccine among children living in Gondar town, Northwest Ethiopia, 2017
Background: Hepatitis B virus infection is a worldwide health problem and highly endemic in developing countries including Ethiopia. Hepatitis B vaccine is included in the routine Expanded Program on Immunization since 2007 in Ethiopia.
Objective: The aim of this study was to assess the sero-protection level of hepatitis B vaccination among children who have received thevaccine.
Methods: A cross-sectional study was conducted among children attending Kindergarten and first cycle elementary school inGondar town. A pre-tested structured questionnaire was used to collect the socio-demographic data. Blood sample was collected and serum separated for anti-HBs,anti-HBc and HBsAg. The data was analyzed using SPSS statistical software version 20. Binary logistic regression analysis was done. P-value less than 0.05 was considered as statistically significant.
Result:Out of 431 children screened, 27 were excluded from analysis because they were positive for anti-HBc(27/431, 6.3%) and/or for HBsAg (18/431 or 4.2%). Out of 404 children, 130 (32.2%) had anti-HBs titers >10 mIU/ml (seroprotected) while 274 (68.8%) had anti-HBs titers <10 mIU/ml (non-protected).
Liang TJ: Hepatitis B: the virus and disease. Hepatology 2009, 49(S5).
Chen G, Li M, Ho R, Chak E, Lau W, Lai P: Identification of hepatitis B virus X gene mutation in Hong Kong patients with hepatocellular carcinoma. Journal of clinical virology 2005, 34(1):7-12.
Doo E, Liang TJ: Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001, 120(4):1000-1008.
Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L: Hepatitis B: Epidemiology and prevention in developing countries. World journal of hepatology 2012, 4(3):74.
Chen S-T, Chang M-H: Epidemiology and Natural History of Hepatitis B in Children. In: Viral Hepatitis in Children. edn.: Springer; 2010: 13-28.
Frame JD: Hepatitis among missionaries in Ethiopia and Sudan: Susceptibles at high risk. JAMA 1968, 203(10):819-826.
Kefene H, Rapicetta M, Rossi G, Bisanti L, Bekura D, Morace G, Palladino P, Di Rienzo A, Conti S, Bassani F: Ethiopian national hepatitis B study. Journal of medical virology 1988, 24(1):75-84.
Rapicetta M, Hailu K, Morace G, Bisanti L, Di Rienzo A, Ciccaglione A, Bekura D, Pasquini P, Rossi G: Prevalence of HBeAg, anti-HBe serological markers and HBV-DNA in asymptomatic carriers in Ethiopia. European journal of epidemiology 1989, 5(4):481-485.
Abebe A, Nokes DJ, Dejene A, Enquselassie F, Messele T, Cutts F: Seroepidemiology of hepatitis B virus in Addis Ababa, Ethiopia: transmission patterns and vaccine control. Epidemiology & Infection 2003, 131(1):757-770.
Berhe N, Myrvang B, Gundersen SG: Intensity of Schistosoma mansoni, hepatitis B, age, and sex predict levels of hepatic periportal thickening/fibrosis (PPT/F): a large-scale community-based study in Ethiopia. The American journal of tropical medicine and hygiene 2007, 77(6):1079-1086.
Demirjian A, Levy O: Safety and efficacy of neonatal vaccination. European journal of immunology 2009, 39(1):36-46.
Ethiopia FMoH: ETHIOPIA NATIONAL EXPANDED PROGRAMME ON IMMUNIZATION COMPREHENSIVE MULTI-YEAR PLAN 2016 -2020. FMOH 2015.
Roukens AH, Visser LG: Hepatitis B vaccination strategy in vaccine low and non-responders: a matter of quantity of quality?Human vaccines 2011, 7(6):654-657.
Ghebrehewet S, Baxter D, Falconer M, Paver K: Intradermal recombinant hepatitis B vaccination (IDRV) for non-responsive healthcare workers (HCWs). Human vaccines 2008, 4(4):280-285.
Dahifar H, Mousavi F, Ghorbani A: Response of booster dose of Cuban Recombinant Hepatitis-B vaccine in nonresponder and hyporesponder children. Pakistan Journal of Medical Sciences 2007, 23(1):23.
Lu C-Y, Ni Y-H, Chiang B-L, Chen P-J, Chang M-H, Chang L-Y, Su I-J, Kuo H-S, Huang L-M, Chen D-S: Humoral and cellular immune responses to a hepatitis B vaccine booster 15–18 years after neonatal immunization. Journal of Infectious Diseases 2008, 197(10):1419-1426.
Bagheri-Jamebozorgi M, Keshavarz J, Nemati M, Mohammadi-Hossainabad S, Rezayati M-T, Nejad-Ghaderi M, Jamalizadeh A, Shokri F, Jafarzadeh A: The persistence of anti-HBs antibody and anamnestic response 20 years after primary vaccination with recombinant hepatitis B vaccine at infancy. Human vaccines & immunotherapeutics 2014, 10(12):3731-3736.
AlFaleh F, AlShehri S, AlAnsari S, AlJeffri M, AlMazrou Y, Shaffi A, Abdo AA: Long-term protection of hepatitis B vaccine 18 years after vaccination. Journal of Infection 2008, 57(5):404-409.
Hamid ATA, Said ZN: Persistence of protection to hepatitis B vaccine and response to booster dose among children and adolescents in Dakahleya-Egypt. Egyptian Journal of Immunology 2014, 21(1):13-26.
El-Sayed B, El-Guindi M, El-Shaarawy A, Salama E-SI, Sobhy GA: Long-term protection of hepatitis B vaccination among Egyptian children. Egyptian Journal of Pediatric Allergy and Immunology (The) 2011, 9(1).
Salama II, Sami SM, Said ZNA, El-Sayed MH, El Etreby LA, Rabah TM, Elmosalami DM, Hamid ATA, Salama SI, Mohsen AMA: Effectiveness of hepatitis B virus vaccination program in Egypt: Multicenter national project. World journal of hepatology 2015, 7(22):2418.
Rey-Cuille M-A, Seck A, Njouom R, Chartier L, Sow HD, Ka AS, Njankouo M, Rousset D, Giles-Vernick T, Unal G: Low immune response to hepatitis B vaccine among children in Dakar, Senegal. PLoS One 2012, 7(5):e38153.
Aghakhani A, Banifazl M, Izadi N, McFarland W, Sofian M, Khadem-Sadegh A, Pournasiri Z, Foroughi M, Eslamifar A, Ramezani A: Persistence of antibody to hepatitis B surface antigen among vaccinated children in a low hepatitis B virus endemic area. World Journal of Pediatrics 2011, 7(4):358-360.
Ahmad S, Manoochehr M, Gholamali S: Prevalence of anti hepatitis B surface antibody among children in Ahvaz, Iran, five years after vaccination. Jundishapur Journal of Microbiology 2011, 2011(1, Winter):0-0.
Rezaei M, Nooripoor S, Ghorbani R, Ramezanshams F, Mamishi S, Mahmoudi S: Seroprotection after hepatitis B vaccination in children aged 1 to 15 years in central province of Iran, Semnan. Journal of preventive medicine and hygiene 2014, 55(1):1-3.
Teoharov P, Kevorkyan A, Petrova N, Baltadzhiev I, Van Damme P: Immune memory and immune response in children from Bulgaria 5–15 years after primary hepatitis B vaccination. The Pediatric infectious disease journal 2013, 32(1):51-53.
Cheang HK, Wong HT, Ho SC, Chew KS, Lee WS: Immune response in infants after universal hepatitis B vaccination: a community-based study in Malaysia. Singapore medical journal 2013, 54(4):224-226.
Eladawy M, Gamal A, Fouad A, El-Faramawy A: Hepatitis B Virus Vaccine immune response in Egyptian children 15-17 years after primary immunization; should we provide a booster dose?Egyptian Journal of Pediatric Allergy and Immunology (The) 2015, 13(2):45-48.
Dahifar H, Ghorbani A, Mousavi F: Anti-HBs in immunized children with Cuban hepatitis B vaccine and impact of booster dose after five years. Pak J Med Sci 2008, 24(4):571-574.
Alexandre KVF, Martins RMB, Souza MMd, Rodrigues IMX, Teles SA: Brazilian hepatitis B vaccine: a six-year follow-up in adolescents. Memórias do Instituto Oswaldo Cruz 2012, 107(8):1060-1063.